U.S. FDA`s New Strategic Priorities 2014 - 1018 (2015)

Topics

• Mandated Areas for Annual Reviews
• The FDA`s "Strategic Priorities" for 2014 and Beyond
• Device, Pharmaceutical and Biological Issues
• Tougher Regulatory Science -- What "Better Science" Really Means
• Major / Pending 510(k) Changes
• General CGMP Issues -- Strengthened Compliance
• Lifecycle Requirements
• Safety / Integrity of Global Supply Chain

Who should Attend

Senior attendees involved or interested in:

• QA
• Corporate Management
• R&D
• RA
• Production
• Engineering
• Marketing